Evidence map›Paper›PMID 38390613›Full record

ArticleImmunoTargets and therapy2024

Males' Access to Human Papillomavirus Vaccination in Resource-Limited Settings.

Wubishet Gezimu, Firomsa Bekele, Teshome Bekana, Ababo Demeke

Open access · goldAbstract read
In one paragraph

Article in ImmunoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Wubishet GezimuDepartment of Nursing, College of Health Science, Mattu University, Mattu, Ethiopia.ORCID 0000-0002-5503-1360
Firomsa BekeleDepartment of Pharmacy, Institute of Health Science, Wallaga University, Nekemte, Ethiopia.ORCID 0000-0002-7855-9838
Teshome BekanaDepartment of Medical Laboratory Sciences, College of Health Science, Mattu University, Mattu, Ethiopia.
Ababo DemekeDepartment of Nursing, College of Medical and Health Science, Dilla University, Dilla, Ethiopia.ORCID 0000-0002-6538-1380
Mattu UniversityDilla University · ETWollega University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human papillomavirus is known to cause cervical and anogenital cancer and benign anogenital and cutaneous warts. Both males and females can contract the virus during sexual intercourse and skin-to-skin contact. Communities in low- and middle-income countries, including Africa, are particularly suffering from human papillomavirus-related diseases, mainly cervical cancer. Vaccination is the most economical and efficient prevention strategy to control human papillomavirus-related diseases. Undoubtedly, to control all types of human papillomavirus-related morbidity and mortality, the entire at-risk, sexually active population needs to be vaccinated regardless of their sex. However, the vaccination program, particularly in Africa, the world's most resource-limited region, is habitually limited to the female population, considering only the burden of cervical cancer. We think that it is impossible to fully mitigate the human papillomavirus infection by vaccinating only the female population, while males can carry and pass the virus. In addition, marginalizing males from this program seems to violate gender inequality and their sexual and reproductive health rights. Hence, we voice the need for global and local governments to consider and customize human papillomavirus vaccination programs for the male population. Also, it is better to consider the male population in different research studies regarding human papillomavirus-related malignant and benign conditions.

Indexed as

HPVmaleresource-limited settingsvaccination

Identifiers

PMID38390613
PMCPMC10882276
OpenAlexW4391887355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.